Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07127926 · ClinicalTrials.gov registry record
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
A clinical trial of Chronic Graft Versus Host Disease, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT07127926: Recruiting study of Chronic Graft Versus Host Disease, sponsored by M.D. Anderson Cancer Center.
NCT07127926 is a study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07127926, a study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
Primary Outcome
Intra patient change in pharmacokinetic parameters will be determined. In addition, it will be evaluated whether crushing the tablet would have clinically significant change in AUC or Cmax, Tmax, which might impact efficacy or safety of belumosudil based on prior belumosudil pharmacokinetic studies. Due to small number of patients in this study, we don't plan to evaluate the impact of crushed belumosudil tablets pharmacokinetics with long-term outcomes.
Conditions Studied
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2027-12-31 |
What NCT07127926 shows while recruiting
NCT07127926 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 116-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07127926 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07127926 about?
NCT07127926 is a clinical study titled "Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD". The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
What is the current status of trial NCT07127926?
This trial is currently recruiting. The enrollment target is 8 participants. The study started on 2026-02-09. Estimated completion is 2027-12-31.
What conditions does trial NCT07127926 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.
Who is sponsoring clinical trial NCT07127926?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07127926 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07127926's enrollment target sits among peer trials
8 31st of 30 the lowest of 30 other Chronic Graft Versus Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Graft Versus Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
RECRUITING
-
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
-
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
RECRUITING · Phase 2
-
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI